angiogenesis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
When stimulated in Oplophorus gracilirostris, OpLuc is secreted from the base of legs and antennae of the deep-sea shrimp as a defense mechanism. This mechanism causes O.gracilirostris release a luminous, bright blue luciferase cloud. There are many species of shrimp which display similar bioluminescence.
periodic table of the elements Also simply the periodic table. A tabular arrangement of the chemical elements organized by their atomic number, electron configuration, and other chemical properties, whose adopted structure shows periodic trends and is used by chemists to derive relationships between various elements as well as predict the properties and behaviors of undiscovered or newly synthesized elements. The first periodic table of the elements was published by Russian chemist Dmitri Mendeleev in 1869.
Uniporters, also known as solute carriers or facilitated transporters, are a type of membrane transport protein that passively transports solutes (small molecules, ions, or other substances) across a cell membrane. It uses facilitated diffusion for the movement of solutes down their concentration gradient from an area of high concentration to an area of low concentration. Unlike active transport, it does not require energy in the form of ATP to function. Uniporters are specialized to carry one specific ion or molecule and can be categorized as either channels or carriers. Facilitated diffusion may occur through three mechanisms: uniport, symport, or antiport. The difference between each mechanism depends on the direction of transport, in which uniport is the only transport not coupled to the transport of another solute. Uniporter carrier proteins work by binding to one molecule or substrate at a time. Uniporter channels open in response to a stimulus and allow the free flow of specific molecules. There are several ways in which the opening of uniporter channels may be regulated:
Sources: en.wikipedia.org
== History == Somapacitan was evaluated in a randomized, double-blind, placebo-controlled trial (NCT02229851) in 300 participants with growth hormone deficiency who had never received growth hormone treatment or had stopped treatment with other growth hormone formulations at least three months before the study. Participants were randomly assigned to receive injections of weekly somapacitan, weekly placebo (inactive treatment), or daily somatropin, an FDA-approved growth hormone. The effectiveness of somapacitan was determined by the percentage change of truncal fat, the fat that is accumulated in the trunk or central area of the body that is regulated by growth hormone and can be associated with serious medical issues. The trial was conducted at 92 sites in 16 countries: the United States, Australia, Germany, India, Japan, Latvia, Lithuania, Malaysia, Poland, Romania, Russian Fed, South Africa, Sweden, Turkey, Ukraine and the United Kingdom. Adult participants were assigned at random to weekly Sogroya or placebo injections for 34 weeks. Neither the participants nor the investigators knew which treatment was given until the end of the trial. One additional group of participants with GHD received daily injections of somatotropin (an approved treatment for GHD). At the end of the 34-week treatment period, truncal fat decreased by 1.06%, on average, among participants taking weekly somapacitan while it increased among participants taking the placebo by 0.47%. In the daily somatropin group, truncal fat decreased by 2.23%.
=== Ethiopian relationship === In 1974 a military-led revolution installed a new regime in Ethiopia. For several years the CLP maintained relations with Ethiopian political activists and wrote reports and articles on developments in Ethiopia and Africa. The Soviet Union supported the new Ethiopian government. However, the CLP was critical of Soviet policies. Given the close relationship between the Ethiopian government and the Soviet Union, the CLP position in Ethiopia was quite precarious. Eventually the CLP had to leave and return to the US.
=== Eggs and hatchlings === C. brunneus lay eggs in a variety of habitats from chalk hills to sandy hills but most commonly lay their eggs in sandy, dry habitats. In the lab, C. brunneus prefer dry and compact substrates composed of fine particles such as sand. They produce the largest number of eggs between 28-35 °C degrees. In theory, smaller eggs should have higher mortality rates because of reduced provisions provided within the egg. However researchers found that egg viability is greater in the southern populations where eggs are smaller. This can be explained by higher overwintering temperatures. Egg size is influenced by a number of factors. As maternal age increases so does egg size. At the beginning of the breeding season females lay smaller eggs compared to the end of the breeding season. Eggs laid in the last part of the breeding season are smaller in size due to deteriorating maternal health. Research suggests that there is no correlation between stage of development and water uptake. While eggs can withstand a large amount of water loss they cannot survive complete desiccation. Therefore, it is not important at what point water is absorbed, it is only important that water is absorbed at some point. A larger egg size generally results in a larger hatchling and adult size. Eggs laid by C. brunneus from late August to early September are the heaviest, hatch the latest, and have heavier hatchlings. While earlier hatchlings are initially smaller, earlier hatchlings achieve a larger body size than later hatchlings.
== Agkistrodon acutus Venom == Common names for this snake include sharp nosed viper, hundred pacer, and snorkel viper. This snake is a pit viper found in the mountains of South Asia. This snake is extremely venomous having a reputation where people can only walk one hundred steps before dying. It is not uncommon for fatalities after being bitten. Bite symptoms include severe local pain and bleeding that may begin almost immediately. This is followed by considerable swelling, blistering, necrosis, and ulceration. Systemic symptoms, which often include heart palpitations, may occur suddenly and relatively soon after the bite. This venom causes people to be forced to amputate limbs and well as mesangiolysis. Mesangiolysis is the process which affects the glomerular mesangium without causing obvious damage to the capillary basement membranes. It is the degeneration and killing of the cells that line the inner layer of the glomerulus, which regulates the globular filtration in the kidney. This causes the kidney to be unable to function, resulting in death. Two hours after the venom is injected into mice, it causes the mice to start mesangiolysis till their kidneys eventually stop working and they die. This venom contains various anticoagulant and hemorrhagic proteins that interfere with the coagulation process. There are four hemorrhagins (acutolysin A, acutolysin B, acutolysin C, and acutolysin D) with acutolysin A being the most portent hemorrhagic.
Sources: en.wikipedia.org
== Biography == Robert Brownlee was born October 21, 1942, in South Dakota. He founded Brownlee Labs in the 1970s, in the San Francisco Bay area, a manufacturer of columns and pumps for high-performance liquid chromatography systems. Bob Brownlee took the initiative "along with Tom Jupille, Steve Bakalyar, Nelson Cooke, Jerry Higgins and Ron Majors" to form the Bay Area Chromatography Colloquium. Bob Stevenson is quoted as saying in his Nine Lives of the California Separation Science Society that Brownlee Labs was "certainly one of the globe's leaders in HPLC column technology." In the 1980s, when Robert Brownlee was diagnosed with AIDS-related complex, he sold his company to Applied Biosystems of Foster City, California, in 1984. (Applied later merged with Perkin-Elmer). Sometime later, he began a new company, which was viewed by Applied as a competitor. A lawsuit was instituted and later settled (Brownlee v. Applied Biosystems, Inc., 1989-1 Trade Cas. (CCH) ¶ 68, (N.D. Cal. 1989) 8,14). In 1990, he was interviewed for an article in The Scientist about Applied Biosystems. "If you produce the first product for these virgins [scientists without such equipment], you have a big value added, and you can charge a big price for your product," Brownlee says. "That's the reason Applied Biosystems did so well." He also formed the Robert Brownlee Foundation, a private family foundation which supports, with grants, K–12 science.
Corticotrophin derived from pituitary glands from pigs, in a gel formulation as well as in a zinc hydrochloride formulation, each first approved in the US in 1955 and subsequently discontinued. In September 2015 ANI Pharmaceuticals and Merck & Co. agreed that ANI would purchase NDA 009854 and NDA 008975 and related trademarks and other assets related to these two versions of corticotrophin from Merck for $75M and ongoing royalties; the transaction closed in January 2016. As of November 2016 ANI was preparing its supplemental NDA to get approval to re-introduce this formulation; in 2015 ANI estimated that the US market for these products was about $1 billion per year, based on sales of Acthar gel. Corticotrophin, first approved in 1952 and subsequently discontinued; as of January 2017 this NDA was under control of Parkedale, a subsidiary of King Pharmaceuticals which is in turn a subsidiary of Pfizer. Corticotrophin branded as "Acthar", was first approved in 1950 and was subsequently discontinued; as of January 2017 this NDA was under control of Sanofi. A corticotrophin was approved in 1957 under NDA 010831, was subsequently discontinued, and as of January 2017 was under control of Organics/Lagrange, a subsidiary of Abbvie via Abbott's acquisition of Solvay's drug business. A generic version under this NDA was approved under ANDA 088772 and was subsequently discontinued, and as of January 2017 was under the control of Actavis. A corticotrophin called H.P. Acthar Gel was approved in 1952 and as of January 2017 was under the control of Mallinckrodt.
thermal abuse, e.g. poor cooling or external fire, electrical abuse, e.g. overcharge or external short circuit, mechanical abuse, e.g. penetration or crash, or internal short circuit, e.g. due to manufacturing flaws or aging. Because of these risks, testing standards are more stringent than those for acid-electrolyte batteries, requiring both a broader range of test conditions and additional battery-specific tests, and there are shipping limitations imposed by safety regulators. There have been battery-related recalls by some companies, including the 2016 Samsung Galaxy Note 7 recall for battery fires. Lithium-ion batteries have a flammable liquid electrolyte. A faulty battery can cause a serious fire. Faulty chargers can affect the safety of the battery because they can destroy the battery's protection circuit. While charging at temperatures below 0 °C, the negative electrode of the cells gets plated with pure lithium, which can compromise the safety of the whole pack. Short-circuiting a battery will cause the cell to overheat and possibly to catch fire. Smoke from thermal runaway in a Li-ion battery is both flammable and toxic. Batteries are tested according to the UL 9540A fire standard, and the TS-800 standard also tests fire propagation from one battery container to adjacent containers.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.